Patents by Inventor Michael Hensel
Michael Hensel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7955600Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.Type: GrantFiled: August 17, 2007Date of Patent: June 7, 2011Assignee: Emergent Product Development UK LimitedInventors: Michael Hensel, David William Holden, Jacqueline Elizabeth Shea
-
Patent number: 7700104Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.Type: GrantFiled: January 23, 2004Date of Patent: April 20, 2010Assignee: Emergent Product Development UK LimitedInventors: Michael Hensel, David William Holden, Jacqueline Elizabeth Shea
-
Patent number: 7524531Abstract: The present invention involves growing diatoms on a surface for the purpose of forming nanoscale-sized siliceous structures on the surface. In accordance with the invention, diatom films are grown on various substrates, which are then fired to remove all organic material from the diatoms and produce a surface coated with intricate, nanoscale-sized structures. The nanoscale-sized structured surface is subsequently treated with a hydrophobic film-forming agent to form a structured self-cleaning surface.Type: GrantFiled: April 27, 2005Date of Patent: April 28, 2009Assignee: Ferro CorporationInventors: Enos A. Axtell, III, George E. Sakoske, Daniel R. Swiler, Michael Hensel, Martin Baumann, David J. Matalka, Gary L. Nuccetelli
-
Patent number: 7429636Abstract: Organohydrogensilicon compounds containing at least one silicon-bonded hydrogen atom per molecule and at least one cyclosiloxane.Type: GrantFiled: April 29, 2003Date of Patent: September 30, 2008Assignee: Dow Corning CorporationInventors: Karmen Karen Asch, Brian Douglas Chapman, Loren Dean Durfee, Robert Michael Hensel, Timothy Paul Mitchell, James Steven Tonge, Paul Cornelius Van Dort
-
Patent number: 7378482Abstract: A composition comprising (A) at least one compound having at least one aliphatic unsaturation; (B) at least one organohydrogensilicon compound containing at least one silicon-bonded hydrogen atom per molecule and (C) a platinum group metal-containing catalyst.Type: GrantFiled: April 29, 2003Date of Patent: May 27, 2008Assignee: Dow Corning CorporationInventors: Karmen Karen Asch, Brian Douglas Chapman, Loren Dean Durfee, Robert Michael Hensel, Timothy Paul Mitchell, James Steven Tonge, Paul Cornelius Van Dort, Loretta Ann Jones
-
Publication number: 20080075739Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.Type: ApplicationFiled: August 17, 2007Publication date: March 27, 2008Inventors: Michael Hensel, David Holden, Jacqueline Shea
-
Publication number: 20060246277Abstract: The present invention involves growing diatoms on a surface for the purpose of forming nanoscale-sized siliceous structures on the surface. In accordance with the invention, diatom films are grown on various substrates, which are then fired to remove all organic material from the diatoms and produce a surface coated with intricate, nanoscale-sized structures. The nanoscale-sized structured surface is subsequently treated with a hydrophobic film-forming agent to form a structured self-cleaning surface.Type: ApplicationFiled: April 27, 2005Publication date: November 2, 2006Applicant: Ferro CorporationInventors: Enos Axtell, George Sakoske, Daniel Swiler, Michael Hensel, Martin Baumann, David Matalka, Gary Nuccetelli
-
Patent number: 6936425Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SP12 gene locus, wherein at least one gene of the SP12 locus is inactivated, wherein the inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is the attenuated gram-negative cell, wherein the cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for the antigen, wherein the cell is capable of expressing the nucleic acid molecule or capable of causing the expression of the nucleic acid molecule in a target cell.Type: GrantFiled: September 3, 1999Date of Patent: August 30, 2005Assignees: Microscience Limited, Imperial College Innovations LimitedInventors: Michael Hensel, David William Holden, Jacqueline Elizabeth Shea
-
Publication number: 20040203039Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.Type: ApplicationFiled: January 23, 2004Publication date: October 14, 2004Applicants: Microscience Limited, Imperial College Innovations LimitedInventors: Michael Hensel, David William Holden, Jacqueline Elizabeth Shea
-
Patent number: 6342215Abstract: A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of: (1) providing a plurality of microorganisms each of which is independently mutated by the insertional inactivation of a gene with a nucleic acid comprising a unique marker sequence so that each mutant contains a different marker sequence, or clones of the said microorganism; (2) providing individually a stored sample of each mutant produced by step (1) and providing individually stored nucleic acid comprising the unique marker sequence from each individual mutant; (3) introducing a plurality of mutants produced by step (1) into the said particular environment and allowing those microorganisms which are able to do so to grow in the said environment; (4) retrieving microorganisms from the said environment or a selected part thereof and isolating the nucleic acid from the retrieved microorganisms; (5) comparing any marker sequences in the nucleic acid isolated in step (4) to the unique mType: GrantFiled: December 1, 1998Date of Patent: January 29, 2002Assignees: Imperial College Innovations Limited, Microscience LimitedInventors: David William Holden, Jacqueline Elizabeth Shea, Michael Hensel